Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting results from its 2023 human oral nicotine study NIC-H22-1. The study compared Lexaria’s DehydraTECH(TM)-Nicotine tobacco-free pouch to two world-leading brands: ZYN(R) and on!(R) ZYN(R) is from Swedish Match and on! comes from Altria Group Inc. subsidiary Helix Innovations LLC. According to the report, DehydraTECH-Nicotine reached maximum blood saturation levels faster than either of the two other brands. In addition, superior subjective performance characteristics were observed in the study. Specifically, Lexaria’s oral nicotine pouch was significantly faster in the median time required to reach comparable maximum nicotine concentrations within the bloodstream than both on! and ZYN, 15% faster and 20.2% faster respectively. According to the announcement, the next step for the company is to seek to commercialize DehydraTECH-Nicotine with suitable industry partners based on its clinical and intellectual property advancements.
“With just five short years of R&D and product development, Lexaria has been able to develop an oral nicotine product that meets or exceeds the performance of the world’s leading existing brands,” said Lexaria Bioscience CEO Chris Bunka in the press release. “This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths. We’ve always had an overwhelming determination and fierce conviction that we can make the world a better place and reduce the carnage caused by smoked cigarettes, and now we have human study data that demonstrates advantages of DehydraTECH processed nicotine relative to the competitive landscape.”
To view the full press release, visit https://ibn.fm/KFsY0
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 35 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.